Af­ter three-decade jour­ney, Geron sees new life in PhI­II da­ta on MDS drug, plots path to ap­proval

Geron, found­ed in 1990 as an an­ti-ag­ing com­pa­ny, has al­most com­plet­ed its meta­mor­pho­sis.

Wednes­day morn­ing, the Bay Area biotech un­veiled that its drug ime­tel­stat suc­ceed­ed in a Phase III tri­al of near­ly 180 pa­tients with low-risk myelodys­plas­tic syn­dromes, or MDS, help­ing more pa­tients go eight weeks with­out blood trans­fu­sions than place­bo. But pa­tients who got the drug al­so ex­pe­ri­enced sig­nif­i­cant side ef­fects, in­clud­ing low platelet and white blood cell counts.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER